GT200000197A - 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida. - Google Patents

2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.

Info

Publication number
GT200000197A
GT200000197A GT200000197A GT200000197A GT200000197A GT 200000197 A GT200000197 A GT 200000197A GT 200000197 A GT200000197 A GT 200000197A GT 200000197 A GT200000197 A GT 200000197A GT 200000197 A GT200000197 A GT 200000197A
Authority
GT
Guatemala
Prior art keywords
isobutiramide
tolil
trifluorometil
morfolin
piridin
Prior art date
Application number
GT200000197A
Other languages
English (en)
Spanish (es)
Inventor
Theresa Maria Ballard
Guy Andrew Higgins
Torsten Hoffmann
Sonia Maria Poli
Andrew Sleight
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of GT200000197A publication Critical patent/GT200000197A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
GT200000197A 1999-11-29 2000-11-28 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida. GT200000197A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99123685 1999-11-29

Publications (1)

Publication Number Publication Date
GT200000197A true GT200000197A (es) 2002-05-22

Family

ID=8239481

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200000197A GT200000197A (es) 1999-11-29 2000-11-28 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6- morfolin-4-il-4-o tolil-piridin-3-il)-isobutiramida.

Country Status (49)

Country Link
EP (1) EP1103545B1 (enExample)
JP (1) JP3480835B2 (enExample)
KR (1) KR100390117B1 (enExample)
CN (1) CN1152016C (enExample)
AR (1) AR033659A1 (enExample)
AT (1) ATE253561T1 (enExample)
AU (1) AU775292B2 (enExample)
BG (1) BG64622B1 (enExample)
BR (1) BRPI0005616B8 (enExample)
CA (1) CA2326529C (enExample)
CO (1) CO5251405A1 (enExample)
CZ (1) CZ299286B6 (enExample)
DE (2) DE60006340T2 (enExample)
DK (1) DK1103545T3 (enExample)
DO (1) DOP2000000106A (enExample)
EA (1) EA004404B1 (enExample)
ES (2) ES2208205T3 (enExample)
FR (1) FR2801590A1 (enExample)
GB (1) GB2356863A (enExample)
GC (1) GC0000151A (enExample)
GE (1) GEP20022763B (enExample)
GT (1) GT200000197A (enExample)
HR (1) HRP20000809A2 (enExample)
HU (1) HU224703B1 (enExample)
ID (1) ID28483A (enExample)
IL (1) IL139868A (enExample)
IS (1) IS2212B (enExample)
IT (1) IT1320120B1 (enExample)
JO (1) JO2298B1 (enExample)
MA (1) MA26754A1 (enExample)
MX (1) MXPA00011672A (enExample)
MY (1) MY127426A (enExample)
NO (1) NO317264B1 (enExample)
NZ (1) NZ508386A (enExample)
OA (1) OA11513A (enExample)
PA (1) PA8507201A1 (enExample)
PE (1) PE20010901A1 (enExample)
PL (1) PL195957B1 (enExample)
PT (1) PT1103545E (enExample)
SG (1) SG97171A1 (enExample)
SI (1) SI1103545T1 (enExample)
SK (1) SK285373B6 (enExample)
SV (1) SV2002000227A (enExample)
TN (1) TNSN00226A1 (enExample)
TR (1) TR200302077T4 (enExample)
UA (1) UA70326C2 (enExample)
UY (1) UY26458A1 (enExample)
YU (1) YU73400A (enExample)
ZA (1) ZA200006964B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL144717A0 (en) 1999-02-24 2002-06-30 Hoffmann La Roche Phenyl-and pyridinyl derivatives
EP1035115B1 (en) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
PT1303490E (pt) * 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives
US20030083345A1 (en) * 2001-07-10 2003-05-01 Torsten Hoffmann Method of treatment and/or prevention of brain, spinal or nerve injury
KR20040077910A (ko) * 2002-01-31 2004-09-07 에프. 호프만-라 로슈 아게 프리프로타키키닌 유전자의 유전자 다형성
ES2291891T3 (es) 2003-07-03 2008-03-01 F. Hoffmann-La Roche Ag Antagonistas duales de nk1/nk3 para tratamiento de esquizofrenia.
US7288658B2 (en) 2003-07-15 2007-10-30 Hoffmann-La Roche Inc. Process for preparation of pyridine derivatives
CN1984891B (zh) 2004-07-06 2012-08-08 弗·哈夫曼-拉罗切有限公司 用作合成nk-1受体拮抗剂的中间体的甲酰胺吡啶衍生物的制备方法
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
CA2602445C (en) 2005-03-23 2013-08-20 F.Hoffmann-La Roche Ag Metabolites for nk-i antagonists for emesis
ATE453384T1 (de) 2005-09-23 2010-01-15 Hoffmann La Roche Neue dosierformulierung
US8093268B2 (en) 2007-01-24 2012-01-10 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5-(5-trifluoromethyl-tetrazol-1-yl-benzyl)-(2S-phenylpiperidin-3S-yl-)
US8426450B1 (en) 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
BR112015021982B1 (pt) 2013-03-15 2022-12-13 Global Blood Therapeutics, Inc Compostos e seus usos para a modulação de hemoglobina
CA2930008A1 (en) 2013-11-08 2015-05-14 Kissei Pharmaceutical Co., Ltd. Carboxymethyl piperidine derivative
AP2016009261A0 (en) 2014-02-07 2016-06-30 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI649307B (zh) 2014-05-07 2019-02-01 日商橘生藥品工業股份有限公司 Cyclohexylpyridine derivative
KR101948238B1 (ko) 2016-08-19 2019-02-14 (주)케어젠 미녹시딜과 펩타이드의 결합체
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
IL112134A (en) * 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
EP0733632B1 (en) * 1995-03-24 2003-06-04 Takeda Chemical Industries, Ltd. Cyclic compounds, their production and use as tachykinin receptor antagonists
US5972938A (en) * 1997-12-01 1999-10-26 Merck & Co., Inc. Method for treating or preventing psychoimmunological disorders
EP1035115B1 (en) * 1999-02-24 2004-09-29 F. Hoffmann-La Roche Ag 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists
US6303790B1 (en) * 1999-11-29 2001-10-16 Hoffman-La Roche Inc. Process for the preparation of pyridine derivatives
PT1303490E (pt) * 2000-07-14 2008-09-04 Hoffmann La Roche Óxidos de aminas como pró-fármacos de antagonistas dosreceptores nk1, de derivados de 4-fenil-piridina
TWI287003B (en) * 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
TWI259180B (en) * 2000-08-08 2006-08-01 Hoffmann La Roche 4-Phenyl-pyridine derivatives

Also Published As

Publication number Publication date
IL139868A0 (en) 2002-02-10
IL139868A (en) 2009-09-01
PL344147A1 (en) 2001-06-04
AR033659A1 (es) 2004-01-07
KR20010051983A (ko) 2001-06-25
GB2356863A (en) 2001-06-06
PA8507201A1 (es) 2002-02-21
CN1152016C (zh) 2004-06-02
GB0028566D0 (en) 2001-01-10
TR200302077T4 (tr) 2004-01-21
PL195957B1 (pl) 2007-11-30
EP1103545A1 (en) 2001-05-30
SK285373B6 (sk) 2006-12-07
AU7178700A (en) 2001-05-31
HU0004725D0 (enExample) 2001-02-28
JO2298B1 (en) 2005-09-12
HRP20000809A2 (en) 2001-12-31
MA26754A1 (fr) 2004-12-20
BRPI0005616B1 (pt) 2017-12-12
YU73400A (sh) 2003-02-28
DE60006340T2 (de) 2004-09-09
GC0000151A (en) 2005-06-29
ZA200006964B (en) 2001-06-05
JP3480835B2 (ja) 2003-12-22
HUP0004725A2 (hu) 2002-04-29
NO20006012D0 (no) 2000-11-28
DOP2000000106A (es) 2002-07-30
ATE253561T1 (de) 2003-11-15
HU224703B1 (en) 2006-01-30
DK1103545T3 (da) 2004-03-15
ES2208205T3 (es) 2004-06-16
NO20006012L (no) 2001-05-30
JP2001151754A (ja) 2001-06-05
NO317264B1 (no) 2004-09-27
BR0005616A (pt) 2001-07-17
ES2171134A1 (es) 2002-08-16
ID28483A (id) 2001-05-31
OA11513A (fr) 2004-02-03
PE20010901A1 (es) 2001-09-20
ITMI20002575A1 (it) 2002-05-29
MY127426A (en) 2006-11-30
GEP20022763B (en) 2002-08-26
EA200001114A2 (ru) 2001-08-27
SK17932000A3 (sk) 2001-11-06
UA70326C2 (en) 2004-10-15
CZ299286B6 (cs) 2008-06-04
UY26458A1 (es) 2001-05-31
CO5251405A1 (es) 2003-02-28
TNSN00226A1 (fr) 2002-05-30
DE60006340D1 (de) 2003-12-11
SI1103545T1 (en) 2004-02-29
SG97171A1 (en) 2003-07-18
CA2326529A1 (en) 2001-05-29
CN1297888A (zh) 2001-06-06
HK1036759A1 (en) 2002-01-18
AU775292B2 (en) 2004-07-29
CZ20004399A3 (cs) 2001-07-11
SV2002000227A (es) 2002-02-05
FR2801590A1 (fr) 2001-06-01
BG64622B1 (bg) 2005-09-30
BG104992A (en) 2001-11-30
EP1103545B1 (en) 2003-11-05
NZ508386A (en) 2003-02-28
CA2326529C (en) 2009-12-22
KR100390117B1 (ko) 2003-07-04
MXPA00011672A (es) 2002-08-20
BRPI0005616B8 (pt) 2021-07-06
IT1320120B1 (it) 2003-11-18
IS2212B (is) 2007-02-15
PT1103545E (pt) 2004-03-31
IS5725A (is) 2001-05-29
EA004404B1 (ru) 2004-04-29
DE10058310A1 (de) 2001-05-31
EA200001114A3 (ru) 2001-12-24

Similar Documents

Publication Publication Date Title
PA8524401A1 (es) DERIVADOS DE 4-Fenil-piridin
UY26782A1 (es) Derivados del benzotiazol
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
LU91145I2 (fr) FIROCOXIB facultativement sous forme d'un sel pharmaceutiquement acceptable (PREVICOX).
UY26754A1 (es) Derivados de la 1, 3, 8, -triaza-spiro (4,5) decan-4-ona
CY1106697T1 (el) Ν-υποκατεστημενες υδρομορφονες και η χρηση αυτων
AR016877A2 (es) 6-ter-butiloxicarbonilaminopiridinas 2-sustituidas y sus sales
BG66085B1 (bg) Фенилаланинови производни
DE60113032D1 (de) Glucocorticoid Rezeptor Modulatoren
PT1337535E (pt) Derivados de benzodiazepina
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
NO985518L (no) Morfinanderivater og medisinsk anvendelse derav
EA200001061A1 (ru) Фармацевтическая композиция
BR0013311A (pt) Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor
UY26851A1 (es) Derivados de la 4-fenilpiridina
DE60217843D1 (de) Ein dioxinoä2,3-güchinolin-9-carbonsäure derivat als nk3 rezeptor antagonist
MX2007004199A (es) Derivados de indol sustituidos con 5-sulfonil-1-piperidinil como antagonistas del receptor 5-ht6 para el tratamiento de trastornos del cns.
ES2171134A1 (es) Procedimiento para la preparacion del pompuesto 2-(3,5-bis-trifluorometil-fenil)-n-,etil-n-(6-morfolin-4-il-o-tolil-priridin-3-il)-isobutiramida. el producto per se, y su uso para la preparacion de medicamentos.
DE60221813D1 (de) Thiazolopyrimidinderivate und deren verwendung als antagonisten des cx3cr1 rezeptors
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
BR0309668A (pt) Imidazolinilmetil aralquilsulfonamidas
CO5570673A2 (es) Compuestos azapoliciclicos condensados con arilo
ATE399164T1 (de) Antagonisten des opioidrezeptors